HOME >> MEDICINE >> NEWS
Phase II study shows combination improves survival of metastatic melanoma patients

CHICAGO -- Two chemotherapy drugs combined with an agent that prevents the growth of blood vessels significantly delayed the spread of tumors in patients with metastatic melanoma, according to study findings presented today at the 2007 American Association of Clinical Oncology (http://www.asco.org/portal/site/ASCO) (ASCO) Annual Meeting.

In this phase II clinical trial of 53 patients, tumor growth was delayed by almost six months, whereas, typically, these cancers begin spreading again eight weeks after chemotherapy treatment, researchers say.

The researchers from Mayo Clinic (http://www.mayo.edu/) and the North Central Cancer Treatment Group (http://ncctg.mayo.edu/) (NCCTG), caution that while the findings are promising, they are preliminary.

"This is the most effective treatment we have ever tested at Mayo Clinic for this type of cancer, but the results need to be validated," says Svetomir Markovic, M.D., Ph.D. (http://mayoresearch.mayo.edu/mayo/research/staff/markovic_sn.cfm), a Mayo Clinic oncologist and the study's principal investigator. "It is important for the public to know there is hope for patients with melanoma."

The study was presented today by Domingo Perez, M.D., the lead author of the study who is a former oncology fellow at Mayo Clinic and is now in private practice in Minneapolis.

"The clinical benefit may seem small, but in the world of melanoma where there is very little progress, this is certainly a strong indication that the combination of chemotherapy with an antiangiogenic agent may be a valid treatment strategy for these patients. But the only way to know this for certain is a head to head comparison with the standard course of treatment," Dr. Perez says.

Melanoma that has metas
'"/>

Contact: Amy Reyes
newsbureau@mayo.edu
507-284-5005
Mayo Clinic
3-Jun-2007


Page: 1 2 3

Related medicine news :

1. GSK announces launch of largest ever Phase III trial in lung cancer treatment
2. MacroChem completes patient enrollment for Phase II trial of EcoNail for treatment of onychomycosis
3. Drug combination proves effective against myeloma in Phase I trial
4. Researchers present Phase 2 clinical results for Acologix AC-100
5. Positive results for ACRUXs lead product in US Phase 3 trial
6. Ebola DNA vaccine produces immune responses in all fully vaccinated volunteers in Phase 1 trial
7. GroPep starts Phase 1 infertility trial
8. Bayer launches Phase III clinical study of Trasylol in elective spinal fusion surgery
9. Joint statement on Savvy Phase 3 trial in Ghana to test the effectiveness of Savvy Gel in preventing HIV
10. NIAID launches first Phase II trial of a global HIV/AIDS vaccine
11. Childhood obesity indicates greater risk of school absenteeism, Penn study reveals

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/13/2017)... ... October 13, 2017 , ... ... certification process to promote standards of excellence for the field of eating disorders, ... March 22 – 25, 2018 in Orlando, Florida at the Omni Resort at ...
(Date:10/13/2017)... ... October 13, 2017 , ... ... alumni Hannah Randall, PharmD ‘17, and Jennifer Huggins, PharmD ’17, along with ... for the primary prevention of cardiovascular diseases during the 15th Annual Women’s ...
(Date:10/13/2017)... ... 13, 2017 , ... Apple Rehab Shelton Lakes , which specializes in ... the facility as part of a disaster drill on October 3rd. , Apple Rehab ... City Emergency Manager, as well as the Connecticut Long Term Care Mutual Aid ...
(Date:10/13/2017)... ... 2017 , ... The Visiting Nurse Association (VNA) of Somerset Hills is proud ... and unique items from across the nation, this holiday-themed event will raise funds and ... the VNA. The boutique will be open Saturday, November 4 (10:00 a.m. – ...
(Date:10/13/2017)... Milford, NJ (PRWEB) , ... October 13, 2017 , ... ... weekend at scenic Alexandria Park in Milford, NJ. This free event, sponsored by ... and physical activity. The fun run is geared towards children of all ages; ...
Breaking Medicine News(10 mins):
(Date:10/11/2017)... , Oct. 11, 2017  True Health, a ... amplified its effort during National Breast Cancer Awareness ... cancer risks. ... Oncology calculated that more than 10 million American ... mutations in BRCA1 or BRCA2 and have not had ...
(Date:10/10/2017)... EXTON, Pa. , Oct. 10, 2017   ... leader in innovative solutions for injectable drug administration, today ... of West,s ID Adapter for improving the intradermal administration ... the Fourth Skin Vaccination Summit in May 2017 by ... Team Lead, Polio Department, World Health Organization (WHO), and ...
(Date:10/4/2017)... , Oct. 4, 2017  South Korean-based healthcare product ... training aide "cprCUBE" on Kickstarter. The device will educate ... cardiac arrests with better efficiency compared to the dated ... real-time feedback on efficacy of the compression for a ... has a goal to raise $5,000. ...
Breaking Medicine Technology:
Cached News: